FDA GLP-1 Warning Letters: How to Read the Sourced Record

Correction, August 14, 2026: we could not substantiate the former claim that FDA issued a 14-letter March-April batch. Our FDA alerts tracker now publishes only individually sourced warning-letter records that link to fda.gov, across the dates represented in the local dataset. The tracker is not exhaustive. Each letter must be read for its own allegations: some address marketing or labeling, while others may address manufacturing or quality. Inclusion does not by itself mean FDA found a medication unsafe.

Quick answer: what to do if you were affected.

• •Step 1: Use our warning and transparency checker to review the finite records we have linked; absence is not proof of safety or compliance
• •Step 2: Contact your prescriber and ask for the dispensing pharmacy's legal name, then review the actual letter and any close-out record before deciding what it means
• •Step 3: Compare current provider and pharmacy disclosures. Embody lists semaglutide from $79 on a selected plan, while Enhance MD starts at $49 for the first month; compounded products are not FDA-approved finished drugs and legality depends on the prescription and pharmacy pathway
• •Step 4: Or ask about brand-name treatment: NovoCare lists the Wegovy pen at $199/mo for the first two low-dose fills, then $349/mo at standard strengths ($399 for HD) and pill from $149/mo, prescription required and dose-dependent; LillyDirect lists Zepbound from $299/mo, with higher-dose pricing. Hers lists Wegovy pill medication from $149 or pen from $199 plus required $39 first-month/$149 ongoing membership
• •Step 5: Report any adverse events to FDA MedWatch at fda.gov/medwatch, this is important for ongoing enforcement

We do not publish a nationwide cumulative total from this dataset because it is a curated, non-exhaustive collection. FDA separately announced 30 telehealth marketing letters on March 3, 2026; that announcement is broader than the individually linked rows in our tracker. For the legal context, see our post-shortage semaglutide guide and brand vs compounded GLP-1 guide.

What the FDA Cited (Most Common Violations)

The sourced letters in our tracker illustrate several distinct categories. Do not assume every letter contains every allegation:

• •Post-shortage compounding conditions. Ending enforcement discretion for shortage-based copies did not create a universal ban; each preparation must satisfy the applicable 503A or 503B and state-law conditions.
• •Semaglutide salt forms. FDA says it is not aware of a lawful basis for using semaglutide sodium or acetate in compounding under the cited statutory conditions.
• •Misleading brand comparisons. Several letters address claims that compounded products were approved, generic, identical, or clinically equivalent to Wegovy, Ozempic, Zepbound, or Mounjaro.
• •Labeling, manufacturing, or record issues. These allegations are letter-specific and should not be inferred from a marketing-only citation.

Why This Matters for Patients

Three reasons the warning-letter record matters beyond the raw number of rows:

• •Telehealth marketing is part of the record. FDA letters can name a marketer or provider even when another entity compounded the medication.
• •Semaglutide and tirzepatide claims both appear. Read the product and conduct cited in the actual letter rather than generalizing across a company or drug class.
• •Open and closed status matter. A warning letter is not a final adjudication, and a later close-out record can materially change the current context.

How to Review Your Current Provider's Public Record

If you're on a compounded GLP-1 today, here are the questions to ask your provider:

• •Which pharmacy fills my prescription? The answer should be a specific 503A or 503B pharmacy name, not 'our network' or 'our partner'.
• •Is that pharmacy on the FDA warning letter list? You can verify at fda.gov/warning-letters or use our Safety Checker.
• •What patient-specific rationale and legal pathway does the prescriber document? The answer should address the actual formulation and applicable 503A or 503B conditions, not a generic claim that all compounded products are legal.
• •What ingredient and concentration are on the label? Confirm the precise formulation, mg/mL concentration, vial size, and syringe units with the dispensing pharmacist; do not infer them from a brand dose.

If a provider cannot answer these questions, pause and ask the prescriber or pharmacist for the records before paying or dosing. Our warning and transparency checker summarizes selected public records; it does not maintain a 'verified compliant' list or certify a provider as safe.

Sources